FDA clears first gene therapy for rare disease; Roche’s breast cancer pill win; Women increasingly turn to GLP-1s.

A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest ...

An experimental gene therapy treatment created at UCLA gave a "bubble girl" born with a rare genetic disorder a new life.

From rare diseases to chronic conditions, epigenetic editing unlocks new ways to control gene activity without altering the genetic code.

A small group of patients with an otherwise incurable form of T‑cell leukemia have seen their cancer driven into remission by ...

Labcorp Holdings ( ($LH) ) has provided an update. On December 10, 2025, Labcorp Holdings announced the retirement of Dr. D. Gary Gilliland from ...

The FDA on Tuesday approved etuvetidigene autotemcel (Waskyra) as the first cell-based gene therapy for patients 6 months and ...

For men with hemophilia B, receipt of gene therapy comprising an infusion of etranacogene dezaparvovec results in sustained endogenous factor IX expression and low annualized bleeding rates over five ...

The rate of severe infections decreased from 2 infections to 0.2 infections per PYO after treatment with etuvetidigene autotemcel.

Aradigm Health, a new benefits platform aimed at easing the financial sting of coverage for cell and gene therapies, has ...

The Food and Drug Administration this week granted approval to a new gene therapy for a rare immune disorder, the maker of which is notably not a drug ...

Based on initial positive results from HOPE-B, etranacogene dezaparvovec became the first gene therapy approved for adults ...